05 sep: Lønstigninger er urealistiske
08 sep: Boligfesten er slut
07-09-2006 11:15:00

STRATEC raises sales and earnings forecast for 2008 to 2010

Birkenfeld, September 7, 2006

STRATEC Biomedical Systems AG today published an ad-hoc announcement

(statutory company announcement) with its sales and earnings forecast

for the 2006 and 2007 financial years. Pursuant to this announcement,

the company assumes that it will be possible to increase its sales

for 2006 to between Euro 65 million and Euro 68 million (sales

corridor) and for 2007 to between Euro 75 million and Euro 78 million

(sales corridor) and to increase its earnings before tax (EBT) to

between Euro 10.5 million and Euro 11 million in 2006 (earnings

corridor) and to between Euro 14 million and Euro 15 million in 2007

(earnings corridor).

In view of the considerable increase in the basis for the 2007

financial year, based on its current planning the company expects to

achieve an annual average growth rate (CAGR) of more than 11% in the

case of sales and of more than 16% for earnings before tax (EBT) from

2008 up to and including 2010.

As a result of the basis effect (higher basis in 2007) and the

shifting of the period under consideration by one year from 2008 the

average annual growth rate (CAGR) for our key sales and earnings

figures is lower in percentage terms, yet higher in absolute terms,

in the long-term forecast (for 2008 to 2010) than in the forecast

published in December 2005 (for 2007 to 2009). Assuming that the

targets stated in our long-term forecast are met, the average annual

growth rate (CAGR) reported by the STRATEC Group for the financial

years from 2000 to 2010 would amount to more than 25% in the case of

sales and to more than 34% in the case of earnings before tax (EBT).

The forecast for 2008 to 2010 takes only limited account of the

conclusion of outstanding new development and supply agreements for

new analyzer system families with existing and new customers.

The new budget figures are considerably higher than the internal

budget targets most recently forecast in December 2005. These

forecast that the sales for the 2006 financial year would increase to

Euro 55 million to Euro 59 million (sales corridor) and that earnings

before tax (EBT) would rise to Euro 8.3 million to Euro 9.2 million

(earnings corridor). An average annual growth rate (CAGR) of more

than 15% in the case of sales and of more than 22% for earnings

before tax (EBT) was forecast for the subsequent 2007 to 2009

financial years.

The annual average growth (CAGR) reported for the financial years

from 2000 up to and including 2005 amounted to more than 32% in terms

of sales and to more than 40% in the case of earnings before tax

(EBT).

About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de)

designs and manufactures fully automated systems for its partners in

the fields of clinical diagnostics and biotechnology. These partners

market such systems, in general together with their own reagents, to

laboratories and research institutes around the world. The company

develops its products on the basis of its own patented technologies.

Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded

in the Prime Standard segment of the Frankfurt Stock Exchange, in the

Gate-M trading segment of the Stuttgart Stock Exchange and on other

exchanges.

The STRATEC Group comprises the listed holding company "STRATEC

Biomedical Systems AG", as well as the subsidiaries "STRATEC NewGen",

"Robion" and "Sanguin".

Further information can be obtained from:

STRATEC Biomedical Systems AG

André Loy, Investor Relations

Gewerbestrasse 37, 75217 Birkenfeld

Germany

Tel: +49 7082 7916-190

Fax: +49 7082 7916-999

E-Mail: ir@stratec-biomedical.de

--- End of Message ---

WKN: 728900; ISIN: DE0007289001;

Listed: Geregelter Markt in Frankfurter Wertpapierbörse, Gate-M in

Börse Stuttgart,

Freiverkehr in Börse Berlin Bremen, Freiverkehr in Bayerische Börse

München,

Freiverkehr in Börse Düsseldorf;

Copyright © Hugin ASA . All rights reserved.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
00:30
VELO
Nogle brugere (Pav3 og ebdrups især) har skrevet lidt om FDA's afvisning af Envarsus. Jeg vil gerne ..
41
14 nov
OMXC20
  Lad mig starte med en meget vigtig pointe: Når man ejer en aktie, ejer man en andel af en virksomh..
32
16 nov
 
Forord Jernmalmens pris er faldet dramatisk siden toppen i år 2011. Med inspirerende tanker fra brug..
30
18 nov
VWS
Normal 0 21 false false false DA X-NONE X-NONE ..
22
19 nov
BIOPOR
  Her følger mine tanker efter Bioporto Q3 regnskab samt efterfølgende investor præsentation   Omsæt..
21
14 nov
OMXC20
Jeg får tit spørgsmålet, "hvad er den bedste indikation på, at et selskab og dets aktiekurs har en s..
20
19 nov
VWS
stop nu det børnehave pjat i er jo ikke en døjt bedre selv. Pokerchamp har ændret fint stil fra tidl..
17
18 nov
EI
Opsang til EI   Det er efterhånden en børnehave i mange af trådene herinde, og jeg kan ikke forstå a..
17
18 nov
GEN
Nå, GEN fik ikke sneget sig ind i late-breaking abstracts på en Gilead sponsoreret idelalisib+ofatum..
15
14 nov
VELO
Veloxisme ?   Når jeg følger Veloxis-debatten, er det lige før jeg tænker, at vi her på EI har opfun..
15

Investorerne dumper Sanofi efter nye træge diabetes-meldinger

20-11-2014 16:44:09
Det franske medicinalselskab Sanofi er i modvind på børsen i Paris torsdag eftermiddag, efter at selskabet endnu engang serverede sløje meldinger om diabetesmar..

Alm. Brand/CEO: Vejrliget udfordrer - København-skybrud dyrt

20-11-2014 13:16:52
Tredje kvartal var dyrt for Alm. Brand i forhold til vejrligsskader, der brutto - altså før reassurance - løb op i en udgift på 153 mio. kr.- Hvis man kikker på..

Aktier/åbning: Coloplast topper mens regnskaber skuffer

20-11-2014 09:21:10
Coloplast topper C20 på en torsdag morgen, der har budt på flere regnskaber uden for C20.Coloplast stiger 0,7 pct. til 514,0 kr. efter godt 10 minutters handel ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo: Stor konkurrent venter lav vækst flere år frem
2
Aktier/åbning: Coloplast topper mens regnskaber skuffer
3
Aktier/tendens: Udlandet sender flade toner til Danmark
4
ØK/CEO: Vi er på ret vej, men ikke i det tempo, vi kunne ønske
5
Aktier/middag: Novo mildner faldet i dansk eliteindeks
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
20. november 2014 21:49:42
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20141120.1 - EUROWEB4 - 2014-11-20 21:49:42 - 2014-11-20 21:49:42 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x